{"id":12715,"date":"2026-02-02T17:58:22","date_gmt":"2026-02-02T14:58:22","guid":{"rendered":"https:\/\/nesiller.com\/focus-77-liquid\/"},"modified":"2026-10-20T14:25:17","modified_gmt":"2026-10-20T11:25:17","slug":"focus-77-liquid","status":"publish","type":"page","link":"https:\/\/nesiller.com\/en\/oncology\/focus-77-liquid\/","title":{"rendered":"Focus 77 Liquid"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Oncology<\/a><\/div>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t

FOCUS 77L (Liquid)<\/h1>\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tTest brochure<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSample report<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

FOCUS 77L<\/strong> is an NGS-based liquid biopsy assay<\/strong> designed for patients with insufficient tissue for molecular testing, when repeat tissue biopsy is not feasible, and\/or in cases of disease progression or suspected acquired resistance. By analyzing ctDNA<\/strong>\u00a0in blood, it enables longitudinal monitoring of the tumor’s molecular profile.<\/p>

The assay demonstrates high concordance with tissue-based genomic profiling and, in accordance with international guidelines (ASCO<\/strong> and ESMO<\/strong>), enables the sensitive detection of resistance-associated alterations that may emerge during treatment.<\/p>

Applications:
<\/strong><\/span><\/p>

  • When tissue samples are insufficient or repeat biopsy is not feasible,<\/li>
  • In cases of disease progression or suspected acquired treatment resistance,<\/li>
  • For the identification of resistance mutations,<\/li>
  • For monitoring the tumor\u2019s molecular profile during treatment,<\/li>
  • For evaluating targeted therapy options.<\/li><\/ul>

    Cancer Type:<\/strong> All solid tumors*
    * For patients with non-small cell lung cancer (NSCLC)<\/strong> or colorectal cancer (CRC)<\/strong> who have progressive disease and insufficient tissue for molecular analysis, liquid biopsy (cfDNA)<\/strong> is recognized by NCCN Guidelines<\/strong> as a critical diagnostic approach.<\/p>

    Technical Specifications<\/b><\/p><\/th><\/tr><\/thead>

    Method:<\/b> NGS – Hybrid Capture<\/span><\/p><\/td>

    Coverage:<\/b> ~10,000x (High Sensitivity)<\/span><\/p><\/td><\/tr>

    Coverage: <\/b>77 Genes (Included in NCCN guidelines)<\/span><\/p>

    ALK, NTRK1, FGFR2, FGFR3, RET, and ROS1 (Fusions); EGFR, ERBB2, and MET (CNVs) genes\u00a0<\/span><\/p>

    Genetic Alterations Analyzed:<\/strong><\/p>

    Detects SNV, Indel, Fusion, and CNV variants with a limit of detection (LoD) down to 0.1%.<\/span><\/p><\/td><\/tr>

    Assay Kit: <\/b>\u00a0ROCHE AVENIO ctDNA kit\u00a0<\/span><\/p><\/td>

    Sequencing System:<\/b> Illumina NextSeq 550 DX (CE-IVD approved)<\/span><\/p><\/td><\/tr>

    Bioinformatics System:<\/b> Avenio<\/span><\/p><\/td>

    Accreditation:<\/b> GENQA External Quality Assessment (EQA) & CAP Accreditation<\/span><\/p><\/td><\/tr>

    Other Features:<\/b><\/p>

    The test features a Positive Predictive Value (PPV) of >99%, significantly minimizing false-positive rates.<\/span><\/p><\/td><\/tr>

    Sample Requirements: <\/b>2 Streck Tubes<\/span><\/p>

    Turnaround Time (TAT):<\/strong> 10\u201314 days<\/p><\/td><\/tr><\/tbody><\/table>

    * Please contact our laboratory for detailed sample submission requirements.
    FOCUS 77 Liquid is performed in accordance with the requirements of the EMQN External Quality Assessment (EQA) program.<\/p>

    \"CAP\"Roche<\/p>

    \"FoundationOne<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

    Oncology FOCUS 77L (Liquid) Test brochure Sample report FOCUS 77L is an […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":12725,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-12715","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/12715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/comments?post=12715"}],"version-history":[{"count":44,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/12715\/revisions"}],"predecessor-version":[{"id":21619,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/12715\/revisions\/21619"}],"up":[{"embeddable":true,"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/pages\/12725"}],"wp:attachment":[{"href":"https:\/\/nesiller.com\/en\/wp-json\/wp\/v2\/media?parent=12715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}